Optcla

Optcla is a clinical-stage biotechnology company focused on developing next-generation optogenetic gene therapies for vision restoration. The company's lead asset, OCL-001, is an AAV-based gene therapy designed to treat end-stage retinitis pigmentosa by expressing light-sensitive proteins in surviving retinal neurons. This approach aims to restore visual function by effectively bypassing lost photoreceptors and recreatng light sensitivity in the eye. Beyond its lead program, Optcla is leveraging its proprietary optogenetic platform to target other blinding conditions, including geographic atrophy in age-related macular degeneration. Based in Shanghai and backed by top-tier healthcare investors, Optcla is a leader in the emerging field of optogenetic medicine in Asia.